Hers vs CoreAge Rx
An in-depth comparison of two leading GLP-1 Providers
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Hers
Best for: coverage in all 50 states, which most of the register will not confirm
Visit Hers →
CoreAge Rx
Best for: semaglutide at $99/month, 48% under the register median
Visit CoreAge Rx →Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, CoreAge Rx opens cheaper — $99/mo against $199, and CoreAge Rx finishes ahead, 9.1 to 6.6. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.
Pricing
Hers
Brand Zepbound from $299/mo medication-only; requires Hers Weight Loss Membership ($149/mo)
CoreAge Rx
Re-verified 2026-08-05: homepage + Preventive Longevity section both show "Semaglutide — Starting at $99/mo", "Same price at every dose"; supersedes stale tiered pricing captured 2026-06-05.
Re-verified 2026-08-05: homepage GLP-1 hero + Preventive Longevity section both show "Tirzepatide — Starting at $149/mo", "Same price at every dose"; supersedes stale tiered pricing captured 2026-06-05.
What’s included
Hers
Covered by the monthly price
Medication
In the price
Clinician visits
Charged on top
Shipping
Not stated
Lab work
Not stated
Coaching
Charged on top
CoreAge Rx
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Score breakdown
Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.
Hers
6.6/10
CoreAge Rx
9.1/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
Features & Coverage
| Feature | Hers | CoreAge Rx |
|---|---|---|
| Starting Price | $199/mo | ✓$99/mo |
| Features | 2 features | ✓6 features |
| States Available | 50 | 50 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | 1 warning | ✓None |
About Hers
Hers is the women-focused telehealth brand from Hims and Hers. It sells compounded semaglutide on a 6-month plan.
Read our full Hers review →About CoreAge Rx
Shipping is free, 2-day, and reaches all 50 states. CoreAge Rx sells LegitScript-verified compounded semaglutide plus tirzepatide, with licensed physicians behind it and 24/7 support. Its own claim: nobody in the compounded GLP-1 space prices more competitively.
Read our full CoreAge Rx review →Pros & Cons
Hers
What we like
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly figure covers medication
- Coverage is published for all 50 states
Watch-outs
- Billed separately from the monthly figure: consult, coaching
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- 1 FDA warning letter matched to this operator in our enforcement register — read what the letter alleges, since a letter discloses a problem rather than disqualifying a seller
- Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
CoreAge Rx
What we like
- Semaglutide at $99 a month, 48% below the $189 median for the same drug and form across this register
- Tirzepatide at $149 a month, 44% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers medication, consult, shipping
- Coverage is published for all 50 states
- No FDA warning letter matched this operator when we searched our enforcement register
Watch-outs
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
CoreAge Rx takes it, 9.1 against 6.6, and it is especially strong on semaglutide at $99/month, 48% under the register median. Hers is no weak second and may fit you better on coverage in all 50 states, which most of the register will not confirm.
Choose Hers if…
You want coverage in all 50 states, which most of the register will not confirm and an opening price near $199 a month.
Choose CoreAge Rx if…
You want semaglutide at $99/month, 48% under the register median and an opening price near $99 a month.
Ready to start? Vetted GLP-1 providers
Vetted telehealth providers that prescribe GLP-1 online.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Trimi Health
Knowing which pharmacy fills the vial — it names VialsRx
From $99/mo
Get started →Strut Health
Semaglutide at $99/month, 48% under the register median
From $99/mo
Get started →Oak
Semaglutide at $119/month, 37% under the register median
From $119/mo
Get started →Hers vs CoreAge Rx: FAQ
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Related comparisons
Continue exploring Hers and CoreAge Rx head-to-heads in the same category.
- Hers vs Trimi Health
- Hers vs Embody
- Hers vs He & She MD
- CoreAge Rx vs Lean Meds
- CoreAge Rx vs NextMeds
- CoreAge Rx vs bmiMD
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.